- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BAY 86-5321/16598Publication without faculty affiliation
- Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes2023 | Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial2023 | Central Library of Charles University, Third Faculty of Medicine
- Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration2023 | Publication without faculty affiliation
- Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic2023 | Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial2023 | Central Library of Charles University, Third Faculty of Medicine